1-20 of 654 Search Results for

Clinical applications of GLP-1 based therapies

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts
Journal: Diabetes
Diabetes 2023;72(Supplement_1):569-P
Published: 20 June 2023
.... Practicing Clinicians Exchange (PCE) developed an educational program on GLP-1 RAs followed by virtual patient simulations to address educational and clinical application needs. Methods: Following a series of live education, 2 virtual patient simulations were released in October 2022. NPs and PAs received...
Journal Articles
Meeting Abstracts
Journal: Diabetes
Diabetes 2022;71(Supplement_1):14-LB
Published: 01 June 2022
... of medication management (anti-hypertensives, SGLT2 inhibitors/GLP1 agonists) and specialist referral was tracked. An interim analysis was performed for 1) Assessing comparability between RWE and a published clinical validation cohort based on KidneyIntelX risk score distribution; 2) Determining if necessary...
Book Chapter
Published: 2024
10.2337/9781580408387.ch04
...., A1C >10% [>86 mmol/mol] or blood glucose ≥300 mg/dL [≥16.7 mmol/L]). E 9.23 In adults with type 2 diabetes, a GLP-1 RA, including a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, is preferred to insulin ( Fig. 4.2 ). A 9.24 If insulin is used, combination therapy...
Book Chapter
Published: 2020
10.2337/9781580406314.ch03
.... The American College of Clinical Endocrinology positions SGLT2 inhibitors and/or GLP-1 as the preferred second-line therapy, after metformin, for most patients with type 2 diabetes who can afford these agents. The American Diabetes Association recommends SGLT2 inhibitors as the preferred second-line agent...
Book
Book Chapter
Published: 2017
10.2337/9781580406482.ch06
... available for treatment of diabetes in the U.S. and six specifically affect postprandial hyperglycemia: sulfonylureas, meglitinides, α-glucosidase inhibitors, glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 inhibitors, and insulin. 55 Three classes of medications, the GLP-1...
Journal Articles
Journal Articles
Book Chapter
Published: 2024
10.2337/9781580408387.ch17
... 10.3, reproduced from that decision pathway, outlines the approach to risk reduction with SGLT2 inhibitor or GLP-1 receptor agonist therapy in conjunction with other traditional, guideline-based preventive medical therapies for blood pressure, lipids, and glycemia and antiplatelet therapy. Figure 17.3...
Book Chapter
Published: 2022
10.2337/9781580407700.ch03
... signals. Further studies are needed to assess whether promising classes of agents, such as GLP-1 agonists and SLGT2 inhibitors, will provide important long-term benefits in terms of cardiac and renal protection in those with type 1 diabetes. Use of adjunctive agents (particularly off-label use...
Book Chapter
Published: 2017
10.2337/9781580406482.ch07
... experiencing hypoglycemia. Information on treatment of hypoglycemia is explored in greater detail in Chapter 13: Nutrition Therapy for Diabetes: Hypoglycemia and Sick Days . Table 7.1 Weight Effects of Glucose-Lowering Medications Medication Class Weight Effects GLP-1 analogs ↓ Pramlintide...
Journal Articles
Journal Articles
Journal: Diabetes
Diabetes 2024;73(10):1566–1582
Published: 08 July 2024
... – 158 7. Rorsman P , Huising MO . The somatostatin-secreting pancreatic δ-cell in health and disease . Nat Rev Endocrinol 2018 ; 14 : 404 – 414 8. Prasad-Reddy L , Isaacs D . A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes...
Book Chapter
Published: 2017
10.2337/9781580406482.ch08
... was published in 2004 and, at that time, approximately one-half of youth with type 2 diabetes treated with medication received insulin and one-half oral agents, most commonly metformin. 55 A clinical trial assessing the use of liraglutide, a glucagon-like peptide-1 (GLP-1) drug, in pediatric...
Journal Articles
Diabetes Care dc242575
Published: 14 January 2025
... microdosing may provide a safer and more consistent alternative, allowing for dose adjustments without signi cant disruptions in therapy. The following scenarios should be considered for clinical application of microdosing. Transitioning between GLP-1RA. Microdosing can help patients transition to a new GLP...
Journal Articles
Journal Articles
Diabetes Spectr 2024;37(4):325–334
Published: 15 November 2024
... by both the American Association of Clinical Endocrinology ( 5 ) and the European Association for the Study of Obesity ( 6 ). Figure 1 Current drug development in obesity based on NRHs. GLP-1, GIP, glucagon, amylin, and PYY are nutrient-stimulated hormones that suppress appetite, and examples...
Journal Articles
Journal Articles